# Molecular insights into antimicrobial resistance and virulence in hospital-associated of vancomycin-resistant Enterococcus faecium isolates in a tertiary hospital in Bangkok Thailand

**Authors:** Thanwa Wongsuk, Anchalee Homkaew, Worrapoj Oonanant, Uraporn Phumisantiphong, Daranee Nutalai, Pranchalee Utaranark, Siriphan Boonsilp

PMC · DOI: 10.1371/journal.pone.0343967 · PLOS One · 2026-03-24

## TL;DR

This study analyzed vancomycin-resistant Enterococcus faecium isolates in Bangkok hospitals to understand their resistance and virulence traits.

## Contribution

The study provides insights into the genetic diversity and resistance mechanisms of VREfm isolates in Thailand.

## Key findings

- The vanA gene was the sole determinant of vancomycin resistance in all isolates.
- ST17 was the dominant lineage among the isolates, belonging to Clonal Complex 17.
- Genome analysis revealed multiple resistance and virulence genes contributing to antimicrobial resistance.

## Abstract

Vancomycin-resistant Enterococci (VRE) are major pathogens causing nosocomial infections globally. This study investigated the genetic characteristics of vancomycin-resistant Enterococcus faecium (VREfm) in Thailand between June and November 2022. Fifty-two clinical VREfm isolates from Bangkok hospitals were analyzed for antimicrobial susceptibility, resistance genes, virulence factors, and genotypes using multilocus sequence typing (MLST). Phylogenetic analysis and goeBURST assessed genetic relationships and population structure. The VRE detection rate was 14.5%, with 97.1% E. faecium and 2.9% E. faecalis, likely reflecting the impact of an active case-finding program. All isolates exhibited resistance to penicillin, ampicillin, vancomycin, levofloxacin, ciprofloxacin, and rifampin. Resistance to erythromycin, high-level streptomycin, teicoplanin, and tetracycline occurred in 98.1%, 53.8%, 51.9%, and 17.3% of isolates, respectively. Chloramphenicol, linezolid, and high-level gentamicin remained effective against all isolates. The vanA gene was the sole resistance determinant detected. Virulence genes esp and hyl were present in 100% and 88.5% of isolates, respectively. MLST identified five sequence types (STs), with ST17 (86.5%) as the dominant lineage, followed by ST262 (7.7%), ST202, ST787, and ST80 (1.9% each). All isolates belonged to Clonal Complex 17. Genome analysis revealed various resistance genes (VanHAX, aac(6')-Ii, aad(6), ant(6)-Ia, msrC, and tetM) and virulence factors (acm, bopD, cpsA/uppS, cpsB/cdsA, ebpA, ebpB, ebpC, efaA, esp, sgrA, and srtC). The vanA gene primarily drives vancomycin resistance in Thailand’s VREfm. Genome analysis reveals antibiotic resistance genes, virulence factors, and mobile genetic elements that may drive antimicrobial resistance, increase diversity, and support adaptation in hospital settings. Ongoing infection control and active surveillance are essential.

## Linked entities

- **Genes:** vanA (vanillate O-demethylase oxygenase) [NCBI Gene 877879], AAD6 (pseudo) [NCBI Gene 850488], msrC (free methionine-(R)-sulfoxide reductase) [NCBI Gene 915160], tet(M) (tetracycline resistance ribosomal protection protein Tet(M)) [NCBI Gene 8154447], acm (collagen-binding MSCRAMM adhesin Acm) [NCBI Gene 66455089], bopD (LacI family transcriptional regulator BopD) [NCBI Gene 60893289], ebpA (endocarditis and biofilm-associated pilus tip protein EbpA) [NCBI Gene 60893488], ebpB (endocarditis and biofilm-associated pilus minor subunit EbpB) [NCBI Gene 60893489], ebpC (endocarditis and biofilm-associated pilus major subunit EbpC) [NCBI Gene 60893490], efaA (Mn/Fe ABC transporter substrate-binding lipoprotein EfaA) [NCBI Gene 63146532], PTPRVP (protein tyrosine phosphatase receptor type V, pseudogene) [NCBI Gene 148713], sgrA (LPXTG-anchored fibrinogen/nidogen-binding adhesin SgrA) [NCBI Gene 66454431], srtC (Ebp pilus assembly class C sortase) [NCBI Gene 60893491]
- **Chemicals:** vancomycin (PubChem CID 14969), penicillin (PubChem CID 2349), ampicillin (PubChem CID 6249), levofloxacin (PubChem CID 149096), ciprofloxacin (PubChem CID 2764), rifampin (PubChem CID 135398735), erythromycin (PubChem CID 12560), streptomycin (PubChem CID 5297), teicoplanin (PubChem CID 133065662), tetracycline (PubChem CID 54675776), chloramphenicol (PubChem CID 5959), linezolid (PubChem CID 3929), gentamicin (PubChem CID 3467)
- **Species:** Enterococcus faecium (taxon 1352), Enterococcus faecalis (taxon 1351)

## Full-text entities

- **Genes:** tetL [NCBI Gene 1450201], vanX [NCBI Gene 13918425], cfr [NCBI Gene 9742423], vanY [NCBI Gene 9988324], vanB [NCBI Gene 6779647], vanZ [NCBI Gene 9715209], VanA [NCBI Gene 13874695], vanB [NCBI Gene 7072424], VanHAX [NCBI Gene 9715205], vanS [NCBI Gene 9715204], ermB [NCBI Gene 9988306], VanHAX [NCBI Gene 6779649], vanA [NCBI Gene 13917379], vanR [NCBI Gene 9988321], asa1 [NCBI Gene 9988313]
- **Diseases:** IS (MESH:C538388), VRE infection (MESH:D007239), UTIs (MESH:D014552), HLSR (MESH:C564013), antibiotic (MESH:D004761), bacteremia (MESH:D016470), endocarditis (MESH:D004696), nosocomial infections (MESH:D003428), AMR (MESH:D060467), intra-abdominal infections (MESH:D059413), multidrug resistance (MESH:D018088)
- **Chemicals:** ATCC 51299 (-), d-alanyl-d-alanine (MESH:C002956), Teicoplanin (MESH:D017334), 2-mercaptoethanol (MESH:D008623), macrolide (MESH:D018942), Erythromycin (MESH:D004917), isoamyl alcohol (MESH:C029683), streptomycin (MESH:D013307), PEN (MESH:C058388), glycopeptide (MESH:D006020), Ciprofloxacin (MESH:D002939), Chelex (MESH:C006960), chloroform (MESH:D002725), phenol (MESH:D019800), aminoglycoside (MESH:D000617), lipopeptide (MESH:D055666), Chloramphenicol (MESH:D002701), tetracyclines (MESH:D013754), fluoroquinolones (MESH:D024841), RIF (MESH:D012293), Penicillin (MESH:D010406), daptomycin (MESH:D017576), AMP (MESH:D000249), ethanol (MESH:D000431), Vancomycin (MESH:D014640), Triton X-100 (MESH:D017830), trimethoprim (MESH:D014295), Tetracycline (MESH:D013752), oxazolidinone (MESH:D023303), sodium dodecyl sulfate (MESH:D012967), LEV (MESH:D007978), lincosamide (MESH:D055231), Ampicillin (MESH:D000667), d-alanyl-d-lactate (MESH:C078877), HCl (MESH:D006851), ansamycin (MESH:D017828), beta-lactams (MESH:D047090), NaCl (MESH:D012965), Linezolid (MESH:D000069349), tigecycline (MESH:D000078304), phosphonic acid (MESH:C570063), Levofloxacin (MESH:D064704), isopropanol (MESH:D019840), water (MESH:D014867), gentamicin (MESH:D005839), Fosfomycin (MESH:D005578), EDTA (MESH:D004492)
- **Species:** Enterococcus raffinosus (species) [taxon 71452], Enterococcus gallinarum (species) [taxon 1353], Escherichia coli (E. coli, species) [taxon 562], Enterococcus hirae (species) [taxon 1354], Enterococcus cecorum (species) [taxon 44008], Homo sapiens (human, species) [taxon 9606], Enterococcus casseliflavus (species) [taxon 37734], Enterococcus faecalis (species) [taxon 1351], Enterococcus faecium (species) [taxon 1352]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13012473/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13012473/full.md

## References

60 references — full list in the complete paper: https://tomesphere.com/paper/PMC13012473/full.md

---
Source: https://tomesphere.com/paper/PMC13012473